Literature DB >> 32268458

Letter to the Editor: Coronavirus Disease 2019 (COVID-19), Infectivity, and the Incubation Period.

Beuy Joob1, Viroj Wiwanitkit2,3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32268458      PMCID: PMC7142000          DOI: 10.3961/jpmph.20.065

Source DB:  PubMed          Journal:  J Prev Med Public Health        ISSN: 1975-8375


× No keyword cloud information.
Dear Editor, We read with great interest the recent publication entitled “A Chinese case of coronavirus disease 2019 (COVID-19) did not show infectivity during the incubation period: based on an epidemiological survey” [1]. Bae concluded that “the epidemiological findings support the claim that the COVID-19 virus does not have infectivity during the incubation period [1].” In fact, a pathogen should not have infectivity during the incubation period or development of disease. However, the exact incubation period of COVID-19 is still unknown. In a recent report by Linton et al. [2], the incubation range was estimated as between 2 days and 14 days with 95% confidence. Exceptional cases might occur with an unusually short or long incubation period. Nevertheless, the reliability of history-taking should also be addressed. How the author was able to confirm the reliability of the patient’s self-reported history is an interesting issue for further discussion. In our country, Thailand, it is not uncommon for patients to disguise their clinical history, which can cause delays in the diagnosis of COVID-19 and exacerbate the local transmission of the disease.
  2 in total

1.  Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data.

Authors:  Natalie M Linton; Tetsuro Kobayashi; Yichi Yang; Katsuma Hayashi; Andrei R Akhmetzhanov; Sung-Mok Jung; Baoyin Yuan; Ryo Kinoshita; Hiroshi Nishiura
Journal:  J Clin Med       Date:  2020-02-17       Impact factor: 4.241

2.  A Chinese Case of COVID-19 Did Not Show Infectivity During the Incubation Period: Based on an Epidemiological Survey.

Authors:  Jong-Myon Bae
Journal:  J Prev Med Public Health       Date:  2020-03-02
  2 in total
  17 in total

1.  Kinetics of cellular and humoral responses to third COVID-19 vaccine in heart transplant recipients: Correspondence.

Authors:  Pathum Sokaromdee; Viroj Wiwanitkit
Journal:  J Heart Lung Transplant       Date:  2022-07-08       Impact factor: 13.569

2.  Re: heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (Moderna) vaccination.

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  Clin Microbiol Infect       Date:  2022-06-13       Impact factor: 13.310

3.  Antibody response to the messenger RNA corona virus disease 2019 vaccine in liver transplant recipients.

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  Hepatol Commun       Date:  2022-04-28

4.  Comment on "Re-infection with SARS-CoV-2 in solid-organ transplant recipients".

Authors:  Pathum Sookaromdee; Viroj Wiwanitkit
Journal:  Transpl Infect Dis       Date:  2022-04-25

5.  Acute kidney injury after COVID-19 vaccines: correspondence.

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

6.  COVID-19 vaccination and lung transplant recipients.

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-06-17

7.  Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - Implications for the omicron variant: Correspondence.

Authors:  Yael Peled; Jignseh K Patel; Arnon Afek; Michal Mandelboim
Journal:  J Heart Lung Transplant       Date:  2022-07-22       Impact factor: 13.569

8.  Antibody response to coronavirus disease 2019 vaccines after allergic reaction to first dose: Correspondence.

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  Ann Allergy Asthma Immunol       Date:  2022-09       Impact factor: 6.248

9.  Comment on "Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination".

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  J Formos Med Assoc       Date:  2022-09-06       Impact factor: 3.871

10.  Third dose of mRNA COVID-19 vaccine and response: Correspondence.

Authors:  Pathum Sookaromdee; Viroj Wiwanitkit
Journal:  Liver Int       Date:  2022-07-30       Impact factor: 8.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.